Regulatory Rescheduling Benefit
Federal rescheduling of medical cannabis announced — expected elimination of 280E tax burden, potential for improved profitability, stronger balance sheet, lower cost of capital, increased access to institutional capital and potential uplisting to a U.S. exchange; viewed as a transformational upside catalyst for the business.
Revenue and Return to YoY Growth
Net revenue from continuing operations of $65.5 million in Q1 FY2026. While slightly down sequentially versus Q4 ($66.1 million), management reports a return to year-over-year growth across continuing operations.
Strong Gross Margin Performance
Gross margin of 52.8% in Q1 versus 52.1% in Q4 — an improvement of ~0.7 percentage points, driven by verticality and operational efficiencies in core markets (New Jersey, Maryland, Pennsylvania).
Improved Adjusted EBITDA and Margin Expansion
Adjusted EBITDA from continuing operations of $17.4 million, representing a 26.5% margin in Q1 versus $16.7 million (25.2%) in Q4 — an increase of $0.7 million and ~1.3 percentage points in margin sequentially.
Consistent Positive Cash Flow and Liquidity
Generated $8.7 million of net cash from continuing operations in Q1 (15th consecutive quarter positive operating cash flow) with operating cash flow yield of 13.3%. Free cash flow was $7.8 million (11th consecutive quarter positive free cash flow) with a free cash flow yield of 10.3%. Cash and cash equivalents increased to $39.1 million from $37.4 million (up ~$1.7 million, +~4.5%).
Strong Market & Brand Execution in Core States
Notable operational performance: Maryland running at ~ $75 million annualized revenue with high-50s gross margins; New Jersey retail strength including full integration of Union Chill and top-25 store rankings; Pennsylvania delivered YoY revenue growth for the 4th consecutive quarter with multiple Apothecarium locations ranking top statewide and record finished goods/unit sales for TerrAscend SKUs. Brand momentum: Kind Tree and Legend driving growth, Legend vape sales grew 'double digits'.
Progress on Michigan Exit and Balance Sheet Repair
Approximately 85% of Michigan asset sales completed; liabilities and debt significantly negotiated down; proceeds primarily used to pay down debt; exit now in final stage via receivership to further mitigate liabilities.
Discipline on G&A and Capital Allocation
G&A reduced to $21.5 million (32.8% of revenue) from $22.8 million (34.4% of revenue) sequentially — a reduction in both absolute dollars (~$1.3 million) and as a percentage of revenue. Capital expenditures were modest at $0.9 million for the quarter.